Understand the source comparison
Comparative Safety Analysis: GHRP-6 vs Other Growth Hormone Secretagogues
Understanding the GHRP-6 acetate safety profile requires context against other GH secretagogues used in research. The table below compares documented adverse event profiles and distinguishing safety characteristics across commonly studied compounds. GHRP-6 Ace
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding the GHRP-6 acetate safety profile requires context against other GH secretagogues used in research. The table below compares documented adverse event profiles and distinguishing safety characteristics across commonly studied compounds.
- GHRP-6 Acetate
- GI disturbance (30–45%), increased appetite (70–90%), transient cortisol spike (60–75%)
- Moderate (20–50% above baseline, resolves in 90–120 min)
- Very High. Most potent appetite stimulant in class
- Mild (15–25% at standard concentrations)
- Well-characterized safety profile; appetite intensity is the primary limitation for metabolic studies
- GHRP-2
- GI disturbance (25–35%), increased appetite (50–70%), cortisol elevation (50–65%)
- Moderate (15–40% above baseline)
- High. Less intense than GHRP-6
- Mild (10–20%)
- Similar mechanism with reduced appetite intensity; preferred for studies where hunger confounds outcomes
- Ipamorelin
- Minimal GI effects (5–10%), no significant appetite change, minimal cortisol elevation (5–15%)
- Minimal (5–15% transient increase)
- Low. Most selective for GH release without ghrelin-like effects
- Low (5–10%)
- Most selective GHS-R agonist; minimal off-target effects make it ideal for isolating GH-mediated outcomes
- Hexarelin
- GI disturbance (35–50%), appetite increase (60–80%), significant cortisol/prolactin elevation (70–85%)
- High (30–60% above baseline)
- High
- Moderate (20–30%)
- Potent GH releaser but highest adverse event frequency; desensitization occurs with chronic use
- CJC-1295 (DAC)
- Injection site reactions (20–35%), vasodilation/flushing (15–25%), minimal appetite change
- Minimal
- Moderate to high (related to DAC component causing depot formation)
- Long-acting GHRH analog; different mechanism (GHRH receptor vs ghrelin receptor); fewer acute adverse events but prolonged half-life complicates washout
- GHRP-6 occupies a middle position in the safety spectrum: more adverse events than highly selective compounds like Ipamorelin, but better characterized and more predictable than broader-acting secretagogues like Hexarelin. The choice among these compounds should be driven by study design. If appetite signaling or cortisol response is a measured endpoint, GHRP-6 confounds results; if the research question requires potent, reliable GH pulses with tolerance for transient adverse events, GHRP-6 performs consistently.
- Researchers combining GH secretagogues with GHRH analogs (CJC 1295 NO DAC or Sermorelin) report synergistic GH release with adverse event profiles reflecting both compounds. The GHRP-6 acetate safety profile remains dominant for acute effects (appetite, cortisol), while the GHRH analog contributes to injection site reactions or flushing.